

Fact Sheet August 2010

Company profile

Mondobiotech holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases.

Through our unique "Search & Match" engine and the collaboration with our worldwide community we have so far discovered more than 300 medicinal product candidates for further exploration in as many as possible of the 7000 rare diseases. Our products feature two major characteristics: they are biologically active peptides of human origin and have platform potentiality for at least 3 orphan indications.

Business model

We are focused on Finding Therapies for Rare Diseases. We license out our product platforms to strategic partners through an aggressive "tradition breaking" licensing strategy of moderate sign-up fees and milestones at development stages and significant milestones and royalties at and after marketing authorization. At present we have 3 product platforms with a total of 6 orphan indications licensed to Intermune and Lung Rx, a subsidiary of United Therapeutics Corp., which has also acquired the rights for 4 additional product candidates within our pipeline.

Management

Fabio Cavalli - Executive Chairman, Chief Business Architect & Founder
Ruggero Gramatica - Chief Executive Officer
Dr. Dorian Bevec - Chief Scientific Officer & Founder
Patrick Pozzorini - Chief Financial Officer & Founder
Vera Cavalli - Chief Pharmaceutical Officer & Founder
Maria Teresa D'Antonangelo Bühlmann - Chief Operating Officer

Boards of directors

Fabio Cavalli - Executive Chairman, Chief Business Architect & Founder
Prinz Michael von und zu Liechtenstein - Vice Chairman & Founder
Ruggero Gramatica - Chief Executive Officer
Robert E. Patterson - Managing Director, Peninsula Venture Silicon Valley
Graf Francis von Seilern-Aspang - CEO Industrie u. Finanzkontor
Vera Cavalli - Chief Pharmaceutical Officer & Founder
Prof. Robert Huber - Nobel Prize Laureate
Prof. Ron Du Bois - Prof. of Respiration Medicine, Imperial College London
Prof. Dr. Thomas Cerny - Head of Oncology, University of St. Gallen
Prof. Dr. Michael A. Keller - Stanford University Librarian
Prof. Dr. Geoffrey West - Distinguished Professor and former President of the Santa Fe Institute

Stock information

Mondobiotech is listed as RARE on SIX, the Swiss Stock Exchange.
Swiss security number: 10191073
ISIN: CH0101910732
SIX ticker symbol: RARE

Strategic alliances and outsourcing

The company partners with relevant communities or parties who are interested in reaching solutions for specific rare diseases. The company outsources through strategic alliances all non-core activities optimizing internal structural flexibility, know-how and costs. Quality of non-core activities is directly controlled by our management and through strict partner selection processes.

We have built strategic alliances with:

- **Bachem (SIX: BANB)**: leading world peptide manufacturer providing the finished products with upscale capability to cover demand when entering the market;
- **23andMe**: leading personal genetics mapping and investigation working jointly to facilitate research of the genetic bases of rare and potentially fatal diseases, such as Pulmonary Arterial Hypertension, Sarcoidosis, and Pulmonary Fibrosis;
- **Lung Rx**: a biotechnology company and subsidiary of United Therapeutics (Nasdaq: UTHR) dedicated to rare pulmonary diseases, has licensed Mondobiotech's product platform Aviptadil for 4 indications and rights to other product platforms.

Validations


6 Orphan Drug Designations granted in USA and Europe,
1 Patent granted for Interferon- γ in Interstitial Lung Diseases.
10 licensing out agreements with Intermune Inc. and Lung Rx LLC (United Therapeutics Corp).
Mondobiotech was awarded Technology Pioneer 2008 by the WEF (World Economic Forum) for its vision, business model and potential impact on world health.

Contacts

Mondobiotech holding AG
T. +41 840 200 010
F. +41 840 200 011
info@mondobiotech.com
www.mondobiotech.com

Fact Sheet August 2010

Pipeline



Location



Dasklosterstans
Mondobiotech headquarter and the incubator of the Search & Match and development activities.

Mondobiotech holding AG
Mürgstrasse 18
CH-6370 Stans
Switzerland
T. +41 840 200 010
F. +41 840 200 011
info@mondobiotech.com
www.mondobiotech.com